Affectis is a biopharmaceutical company developing novel drugs for the treatment of psychiatric and neuroinflammatory disorders.
Affectis' unique capabilities in drug discovery and behavioural pharmacology allow the company to develop drugs with innovative mechanisms of action based on pioneering findings.
Today's psychiatric market is dominated by therapeutic concepts that are decades old. Shortcomings of existing drugs range from delayed onset of action to a significant rate of non-responders and unwanted side effects. Affectis' programs carry the promise of bringing to market entirely new classes of drugs that would address and satisfy unmet needs.

Web: www.affectis.com